{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:04:04Z","timestamp":1791489844086,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00393-019-0622-y","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T10:02:26Z","timestamp":1553508146000},"page":"249-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Osteoporose \u2013 h\u00e4ufige Komorbidit\u00e4t bei Rheumapatienten","Osteoporosis\u2014frequent comorbidity in patients with rheumatism"],"prefix":"10.1007","volume":"78","author":[{"given":"M.","family":"Gaubitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"key":"622_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00393-016-0104-4","volume":"75","author":"U Lange","year":"2016","unstructured":"Lange U, Schett G (2016) Osteoporose. Z\u00a0Rheumatol 75:442\u2013443","journal-title":"Z Rheumatol"},{"key":"622_CR2","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00393-011-0927-y","volume":"71","author":"M Rauner","year":"2012","unstructured":"Rauner M, Hofbauer LC, Aringer M (2012) Lokale und systemische Knocheneffekte bei rheumatoider Arthritis. Z\u00a0Rheumatol 71:869\u2013874","journal-title":"Z Rheumatol"},{"key":"622_CR3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00393-016-0101-7","volume":"75","author":"KW Frommer","year":"2016","unstructured":"Frommer KW, Neumann E, Lange U (2016) Entz\u00fcndung und Knochen. Z\u00a0Rheumatol 75:444\u2013450","journal-title":"Z Rheumatol"},{"issue":"4","key":"622_CR4","doi-asserted-by":"publisher","first-page":"R154","DOI":"10.1186\/ar3107","volume":"12","author":"SY Kim","year":"2010","unstructured":"Kim SY, Schneeweiss S, Liu J et al (2010) Risk of osteoporotic fracture in a\u00a0large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 12(4):R154. \n                    https:\/\/doi.org\/10.1186\/ar3107","journal-title":"Arthritis Res Ther"},{"key":"622_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00223-018-0401-9","volume":"102","author":"AM Dubrovsky","year":"2018","unstructured":"Dubrovsky AM, Lim MJ, Lane NE (2018) Osteoporosis in rheumatic diseases: Anti-rheumatic drugs and the skeleton. Calcif Tissue Int 102:607\u2013618","journal-title":"Calcif Tissue Int"},{"key":"622_CR6","volume-title":"DVO Leitlinie Osteoporose 2017","author":"Dachverband Osteologie e. V.","year":"2017","unstructured":"Dachverband Osteologie e. V. (2017) DVO Leitlinie Osteoporose 2017. \n                    http:\/\/www.dv-osteologie.org\/dvo_leitlinien\/dvo-leitlinie-2017\n                    \n                  . Zugegriffen: 28. Nov. 2018"},{"key":"622_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00393-014-1410-3","volume":"73","author":"K Albrecht","year":"2014","unstructured":"Albrecht K (2014) Gender-spezifische Unterschiede der Komorbidit\u00e4t bei rheumatoider Arthritis. Z\u00a0Rheumatol 73:607\u2013614","journal-title":"Z Rheumatol"},{"key":"622_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00393-011-0872-9","volume":"70","author":"I Heberlein","year":"2011","unstructured":"Heberlein I, Demary W, Bloching H et\u00a0al (2011) Prophylaxis and treatment of osteoporosis in patients with rheumatoid arthritis (ORA study). Z\u00a0Rheumatol 70:793\u2013798","journal-title":"Z Rheumatol"},{"key":"622_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00296-008-0576-x","volume":"28","author":"P Oelzner","year":"2008","unstructured":"Oelzner P, Schwabe A, Lehmann G et\u00a0al (2008) Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int 28:1143\u20131150","journal-title":"Rheumatol Int"},{"key":"622_CR10","volume-title":"Kerndokumentation der Deutschen Rheumazentren 2016","author":"Statistisches Bundesamt","year":"2018","unstructured":"Statistisches Bundesamt (2018) Kerndokumentation der Deutschen Rheumazentren 2016. \n                    http:\/\/www.gbe-bund.de\/gbe10\/abrechnung.prc_abr_test_logon?p_uid=gast&p_aid=0&p_knoten=FID&p_sprache=D&p_suchstring=7015\n                    \n                   (Erstellt: 8. Mai 2018)"},{"issue":"Suppl 2","key":"622_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn C, Holle J, Iking-Konert C et al (2018) S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z\u00a0Rheumatol 77(Suppl 2):35\u201353","journal-title":"Z Rheumatol"},{"key":"622_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00393-016-0102-6","volume":"75","author":"A Knauerhase","year":"2016","unstructured":"Knauerhase A, Willenberg HS (2016) Neue Antiosteoporotika am Horizont. Z\u00a0Rheumatol 75:466\u2013470","journal-title":"Z Rheumatol"},{"issue":"69","key":"622_CR13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acr.23279","volume":"2017","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA et al (2017) American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2017(69):1095\u20131110","journal-title":"Arthritis Care Res"},{"key":"622_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-214626","author":"A Muthukrishnan","year":"2016","unstructured":"Muthukrishnan A, Kumar LB, Ramalingam G (2016) Medication-related osteonecrosis of the jaw: A\u00a0dentist\u2019s nightmare. Bmj Case Rep. \n                    https:\/\/doi.org\/10.1136\/bcr-2016-214626","journal-title":"Bmj Case Rep"},{"key":"622_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler D et al (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J\u00a0Clin Densitom 20:8\u201324","journal-title":"J Clin Densitom"},{"key":"622_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/jbmr.2693","volume":"31","author":"X Zhang","year":"2016","unstructured":"Zhang X, Hamadeh IS, Song S et\u00a0al (2016) Osteonecrosis of the jaw in the United States food and drug administration\u2019s adverse event reporting system (FAERS). J\u00a0Bone Miner Res 31:336\u2013340","journal-title":"J Bone Miner Res"},{"key":"622_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of Denosumab: A\u00a0post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J\u00a0Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"622_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00393-018-0549-8","volume":"77","author":"A Pfeil","year":"2018","unstructured":"Pfeil A, Lehmann G, Lange U (2018) Update DVO-Leitlinie 2017 \u201eProphylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und M\u00e4nnern\u201c. Z\u00a0Rheumatol 77:759\u2013763","journal-title":"Z Rheumatol"},{"key":"622_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of Denosumab therapy for osteoporosis: A\u00a0systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"key":"622_CR20","first-page":"96","volume-title":"Fachwisssen Osteologie","author":"J Amann","year":"2018","unstructured":"Amann J, Lang A, Hoff P et\u00a0al (2018) Glukokortikoidinduzierte Osteoporose. In: Kurth A, Lange U (Hrsg) Fachwisssen Osteologie. Elsevier, M\u00fcnchen, S\u00a096\u201399"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0622-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-0622-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-0622-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:22:35Z","timestamp":1585009355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-0622-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-0622-y","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"25 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Gaubitz erhielt Honorare f\u00fcr Vortr\u00e4ge und Beratung von Abbvie, Amgen, BMS, Chugai, Hexal, Janssen, Lilly, Medac, MSD, Pfizer, Roche, Sanofi, Servier, SOBI und UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurde vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}